Gerd Pluschke

List of Publications by Year
in descending order

138 papers	3,910 citations	101543 36 h-index	175258 52 g-index
145 all docs	145 docs citations	145 times ranked	2864 citing authors

#	Article	IF	Citations
1	Buruli Ulcer (M. ulcerans Infection): New Insights, New Hope for Disease Control. PLoS Medicine, 2005, 2, e108.	8.4	205
2	On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics, 2012, 13, 258.	2.8	139
3	Oral Treatment for Mycobacterium ulcerans Infection: Results From a Pilot Study in Benin. Clinical Infectious Diseases, 2011, 52, 94-96.	5.8	109
4	Induction of Parasite Growth-Inhibitory Antibodies by a Virosomal Formulation of a Peptidomimetic of Loop I from Domain III of Plasmodium falciparum Apical Membrane Antigen 1. Infection and Immunity, 2003, 71, 4749-4758.	2.2	91
5	Clonal Waves of Neisseria Colonisation and Disease in the African Meningitis Belt: Eight- Year Longitudinal Study in Northern Ghana. PLoS Medicine, 2007, 4, e101.	8.4	81
6	Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans. BMC Evolutionary Biology, 2007, 7, 177.	3.2	81
7	Geographic Distribution, Age Pattern and Sites of Lesions in a Cohort of Buruli Ulcer Patients from the MapÃ© Basin of Cameroon. PLoS Neglected Tropical Diseases, 2013, 7, e2252.	3.0	73
8	Genomic Diversity and Evolution of Mycobacterium ulcerans Revealed by Next-Generation Sequencing. PLoS Pathogens, 2009, 5, e1000580.	4.7	68
9	The Nâ€™-Terminal Domain of Glyceraldehyde-3-Phosphate Dehydrogenase of the Apicomplexan Plasmodium falciparum Mediates GTPase Rab2-Dependent Recruitment to Membranes. Biological Chemistry, 2003, 384, 1227-37.	2.5	66
10	Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer. Nature Communications, 2018, 9, 5370.	12.8	64
11	Global Phylogenomic Analysis of NonencapsulatedStreptococcus pneumoniaeReveals a Deep-Branching Classic Lineage That Is Distinct from Multiple Sporadic Lineages. Genome Biology and Evolution, 2014, 6, 3281-3294.	2.5	63
12	The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chemical Biology, 2017, 12, 1297-1307.	3.4	62
13	Secondary Buruli Ulcer Skin Lesions Emerging Several Months after Completion of Chemotherapy: Paradoxical Reaction or Evidence for Immune Protection?. PLoS Neglected Tropical Diseases, 2011, 5, e1252.	3.0	62
14	Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children. PLoS ONE, 2011, 6, e22273.	2.5	61
15	Passive Immunoprotection of Plasmodium falciparum-Infected Mice Designates the CyRPA as Candidate Malaria Vaccine Antigen. Journal of Immunology, 2012, 188, 6225-6237.	0.8	60
16	Development of Highly Organized Lymphoid Structures in Buruli Ulcer Lesions after Treatment with Rifampicin and Streptomycin. PLoS Neglected Tropical Diseases, 2007, 1, e2.	3.0	58
17	Use of the Immunodominant 18-Kilodalton Small Heat Shock Protein as a Serological Marker for Exposure to Mycobacterium ulcerans. Vaccine Journal, 2006, 13, 1314-1321.	3.1	57
18	A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA). Vaccine, 2014, 32, 2688-2695.	3.8	55

#	Article	IF	Citations
19	The genome, evolution and diversity of Mycobacterium ulcerans. Infection, Genetics and Evolution, 2012, 12, 522-529.	2.3	54
20	A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers. PLoS ONE, 2007, 2, e1018.	2.5	53
21	Structure-Activity Relationship Studies on the Macrolide Exotoxin Mycolactone of Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2013, 7, e2143.	3.0	53
22	Exploiting Conformationally Constrained Peptidomimetics and an Efficient Human-Compatible Delivery System in Synthetic Vaccine Design. ChemBioChem, 2001, 2, 838.	2.6	52
23	Evaluation of Decontamination Methods and Growth Media for Primary Isolation of Mycobacterium ulcerans from Surgical Specimens. Journal of Clinical Microbiology, 2004, 42, 5875-5876.	3.9	52
24	Contiguous spread ofMycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. Journal of Pathology, 2006, 208, 119-128.	4.5	52
25	Single Nucleotide Polymorphism Typing of Mycobacterium ulcerans Reveals Focal Transmission of Buruli Ulcer in a Highly Endemic Region of Ghana. PLoS Neglected Tropical Diseases, 2010, 4, e751.	3.0	51
26	Emergence of a New Epidemic Neisseria meningitidis Serogroup A Clone in the African Meningitis Belt: High-Resolution Picture of Genomic Changes That Mediate Immune Evasion. MBio, 2014, 5, e01974-14.	4.1	51
27	Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. ELife, 2017, 6, .	6.0	50
28	A Virosomal Malaria Peptide Vaccine Elicits a Long-Lasting Sporozoite-Inhibitory Antibody Response in a Phase 1a Clinical Trial. PLoS ONE, 2007, 2, e1278.	2.5	49
29	Improved Protective Efficacy of a Species-Specific DNA Vaccine Encoding Mycolyl-Transferase Ag85A from Mycobacterium ulcerans by Homologous Protein Boosting. PLoS Neglected Tropical Diseases, 2008, 2, e199.	3.0	48
30	Secondary Bacterial Infections of Buruli Ulcer Lesions Before and After Chemotherapy with Streptomycin and Rifampicin. PLoS Neglected Tropical Diseases, 2013, 7, e2191.	3.0	48
31	Phase Change Material for Thermotherapy of Buruli Ulcer: A Prospective Observational Single Centre Proof-of-Principle Trial. PLoS Neglected Tropical Diseases, 2009, 3, e380.	3.0	48
32	A Ringâ€Closing Metathesis (RCM)â€Based Approach to Mycolactonesâ€…A/B. Chemistry - A European Journal, 2011, 17, 13017-13031.	3.3	45
33	Mycobacterium ulcerans Persistence at a Village Water Source of Buruli Ulcer Patients. PLoS Neglected Tropical Diseases, 2014, 8, e2756.	3.0	43
34	Buruli ulcer disease: prospects for a vaccine. Medical Microbiology and Immunology, 2009, 198, 69-77.	4.8	42
35	Immunosuppression and treatment-associated inflammatory response in patients withMycobacterium ulceransinfection (Buruli ulcer). Expert Opinion on Biological Therapy, 2009, 9, 187-200.	3.1	39
36	Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions. PLoS Pathogens, 2015, 11, e1005011.	4.7	38

#	Article	IF	Citations
37	Antibody-Mediated Neutralization of the Exotoxin Mycolactone, the Main Virulence Factor Produced by Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2016, 10, e0004808.	3.0	38
38	A Virosome-Mimotope Approach to Synthetic Vaccine Design and Optimization: Synthesis, Conformation, and Immune Recognition of a Potential Malaria-Vaccine Candidate. Angewandte Chemie - International Edition, 2003, 42, 2368-2371.	13.8	37
39	Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine, 2013, 31, 1453-1457.	3.8	35
40	Structure-Activity-Based Design of a Synthetic Malaria Peptide Eliciting Sporozoite Inhibitory Antibodies in a Virosomal Formulation. Chemistry and Biology, 2007, 14, 577-587.	6.0	34
41	Sero-Epidemiology as a Tool to Screen Populations for Exposure to Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2012, 6, e1460.	3.0	34
42	Independent Loss of Immunogenic Proteins in Mycobacterium ulcerans Suggests Immune Evasion. Vaccine Journal, 2008, 15, 598-606.	3.1	33
43	Histopathological Changes and Clinical Responses of Buruli Ulcer Plaque Lesions during Chemotherapy: A Role for Surgical Removal of Necrotic Tissue?. PLoS Neglected Tropical Diseases, 2011, 5, e1334.	3.0	33
44	Late Onset of the Serological Response against the 18 kDa Small Heat Shock Protein of Mycobacterium ulcerans in Children. PLoS Neglected Tropical Diseases, 2014, 8, e2904.	3.0	31
45	Infiltrating leukocytes surround early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria. Virulence, 2017, 8, 1918-1926.	4.4	31
46	Microheterogeneity of serogroup A (subgroup III) Neisseria meningitidis during an outbreak in northern Ghana. Tropical Medicine and International Health, 2000, 5, 280-287.	2.3	30
47	Interferon-Î³ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice. PLoS Neglected Tropical Diseases, 2016, 10, e0004450.	3.0	30
48	Combining PCR with Microscopy to Reduce Costs of Laboratory Diagnosis of Buruli Ulcer. American Journal of Tropical Medicine and Hygiene, 2011, 85, 900-904.	1.4	28
49	Local Activation of the Innate Immune System in Buruli Ulcer Lesions. Journal of Investigative Dermatology, 2007, 127, 638-645.	0.7	27
50	Local Heat Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single Center Non Comparative Clinical Trial. Clinical Infectious Diseases, 2016, 62, 342-350.	5.8	27
51	The global distribution and diversity of protein vaccine candidate antigens in the highly virulent Streptococcus pnuemoniae serotype 1. Vaccine, 2017, 35, 972-980.	3.8	27
52	Region-specific diversification of the highly virulent serotype 1 Streptococcus pneumoniae. Microbial Genomics, 2015, 1, e000027.	2.0	27
53	An efficient system to generate monoclonal antibodies against membrane-associated proteins by immunisation with antigen-expressing mammalian cells. BMC Biotechnology, 2010, 10, 87.	3.3	26
54	Locally Confined Clonal Complexes of Mycobacterium ulcerans in Two Buruli Ulcer Endemic Regions of Cameroon. PLoS Neglected Tropical Diseases, 2015, 9, e0003802.	3.0	26

#	Article	IF	Citations
55	Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms. Frontiers in Microbiology, 2017, 8, 1903.	3.5	26
56	Mycolactone: More than Just a Cytotoxin. , 2019, , 117-134.		26
57	Mycobacterium ulcerans Disease (Buruli Ulcer): Potential Reservoirs and Vectors. Current Clinical Microbiology Reports, 2015, 2, 35-43.	3.4	25
58	A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A. Vaccines, 2015, 3, 850-874.	4.4	24
59	Identification of the Mycobacterium ulcerans Protein MUL_3720 as a Promising Target for the Development of a Diagnostic Test for Buruli Ulcer. PLoS Neglected Tropical Diseases, 2015, 9, e0003477.	3.0	24
60	Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 687-696.	3.2	23
61	Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer. PLoS Neglected Tropical Diseases, 2016, 10, e0004431.	3.0	23
62	Experimental Infection of the Pig with Mycobacterium ulcerans: A Novel Model for Studying the Pathogenesis of Buruli Ulcer Disease. PLoS Neglected Tropical Diseases, 2014, 8, e2968.	3.0	22
63	Development of a bead-based Luminex assay using lipopolysaccharide specific monoclonal antibodies to detect biological threats from Brucella species. BMC Microbiology, 2015, 15, 198.	3.3	22
64	Understanding pneumococcal serotype 1 biology through population genomic analysis. BMC Infectious Diseases, 2016, 16, 649.	2.9	22
65	Optimized DNA Preparation from Mycobacteria. Cold Spring Harbor Protocols, 2010, 2010, pdb.prot5408.	0.3	21
66	Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model. PLoS Neglected Tropical Diseases, 2016, 10, e0004678.	3.0	21
67	The immunology of other mycobacteria: M. ulcerans, M. leprae. Seminars in Immunopathology, 2020, 42, 333-353.	6.1	21
68	Community knowledge, perceptions and attitudes regarding leprosy in rural Cameroon: The case of Ekondotiti and Mbonge health districts in the South-west Region. PLoS Neglected Tropical Diseases, 2018, 12, e0006233.	3.0	21
69	Rhoptry-Associated Protein 1-Binding Monoclonal Antibody Raised against a Heterologous Peptide Sequence Inhibits Plasmodium falciparum Growth In Vitro. Infection and Immunity, 2001, 69, 2558-2568.	2.2	20
70	Genomic analysis of ST88 community-acquired methicillin resistantStaphylococcus aureusin Ghana. PeerJ, 2017, 5, e3047.	2.0	20
71	Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment. PLoS Neglected Tropical Diseases, 2015, 9, e0003996.	3.0	19
72	Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease. PLoS Neglected Tropical Diseases, 2015, 9, e0004011.	3.0	19

#	Article	IF	Citations
73	Socio-Environmental Factors Associated with the Risk of Contracting Buruli Ulcer in TiassalÃ©, South CÃ´te dâ€™Ivoire: A Case-Control Study. PLoS Neglected Tropical Diseases, 2016, 10, e0004327.	3.0	19
74	Assessing and managing wounds of Buruli ulcer patients at the primary and secondary health care levels in Ghana. PLoS Neglected Tropical Diseases, 2017, 11, e0005331.	3.0	19
75	Primary cultivation: factors affecting contamination and Mycobacterium ulcerans growth after long turnover time of clinical specimens. BMC Infectious Diseases, 2014, 14, 636.	2.9	18
76	Spatial Distribution of Mycobacterium ulcerans in Buruli Ulcer Lesions: Implications for Laboratory Diagnosis. PLoS Neglected Tropical Diseases, 2016, 10, e0004767.	3.0	18
77	Characteristics and epidemiological profile of Buruli ulcer in the district of TiassalÃ©, south CÃ´te dâ€™Ivoire. Acta Tropica, 2017, 175, 138-144.	2.0	18
78	Burden and Historical Trend of Buruli Ulcer Prevalence in Selected Communities along the Offin River of Ghana. PLoS Neglected Tropical Diseases, 2016, 10, e0004603.	3.0	18
79	Synthetic glycosylphosphatidylinositol microarray reveals differential antibody levels and fine specificities in children with mild and severe malaria. Bioorganic and Medicinal Chemistry, 2010, 18, 3747-3752.	3.0	17
80	Mycobacterium ulcerans Disease. , 2014, , 519-531.e2.		17
81	Epidemiology and disease burden of Buruli ulcer: a review. Research and Reports in Tropical Medicine, 0, , 59.	1.4	17
82	Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA. Malaria Journal, 2016, 15, 161.	2.3	17
83	Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals. Frontiers in Immunology, 2021, 12, 747594.	4.8	17
84	DNA Methylation Assessed by SMRT Sequencing Is Linked to Mutations in Neisseria meningitidis Isolates. PLoS ONE, 2015, 10, e0144612.	2.5	16
85	Toward a Single-Dose Cure for Buruli Ulcer. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	16
86	Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models. Npj Vaccines, 2020, 5, 9.	6.0	16
87	Generation of chimeric monoclonal antibodies from mice that carry human immunoglobulin CÎ³1 heavy or CÎº light chain gene segments. Journal of Immunological Methods, 1998, 215, 27-37.	1.4	15
88	Comparative Study of Activities of a Diverse Set of Antimycobacterial Agents against Mycobacterium tuberculosis and Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 2016, 60, 3132-3137.	3.2	15
89	Buruli Ulcer in Cameroon: The Development and Impact of the National Control Programme. PLoS Neglected Tropical Diseases, 2016, 10, e0004224.	3.0	15
90	Synthesis, Solution Structure and Immune Recognition of an Epidermal Growth Factor-Like Domain from Plasmodium falciparum Merozoite Surface Protein-1. ChemBioChem, 2006, 7, 1943-1950.	2.6	14

#	Article	IF	Citations
91	Immunohistochemical Monitoring of Wound Healing in Antibiotic Treated Buruli Ulcer Patients. PLoS Neglected Tropical Diseases, 2014, 8, e2809.	3.0	14
92	A Sero-epidemiological Approach to Explore Transmission of Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2016, 10, e0004387.	3.0	14
93	Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-NaÃ¯ve, but Not in Vaccinated Individuals. Frontiers in Immunology, 2021, 12, 732146.	4.8	14
94	Screening of Antifungal Azole Drugs and Agrochemicals with an Adapted alamarBlue-Based Assay Demonstrates Antibacterial Activity of Croconazole against Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 2012, 56, 6410-6413.	3.2	13
95	Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study. American Journal of Tropical Medicine and Hygiene, 2015, 93, 216-223.	1.4	13
96	Mycobacterium ulcerans Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates. PLoS ONE, 2016, 11, e0167059.	2.5	12
97	Buruli Ulcer: History and Disease Burden. , 2019, , 1-41.		12
98	Buruli ulcer: The Efficacy of Innate Immune Defense May Be a Key Determinant for the Outcome of Infection With Mycobacterium ulcerans. Frontiers in Microbiology, 2020, 11, 1018.	3.5	12
99	Genetic diversification of Neisseria meningitidis during waves of colonization and disease in the meningitis belt of sub-Saharan Africa. Vaccine, 2007, 25, A18-A23.	3.8	11
100	Development of Dengue Virus Serotypeâ€“Specific NS1 Capture Assays for the Rapid and Highly Sensitive Identification of the Infecting Serotype in Human Sera. Journal of Immunology, 2018, 200, 3857-3866.	0.8	11
101	Configurationally Stabilized Analogs of M. ulcerans Exotoxins Mycolactones A and B Reveal the Importance of Side Chain Geometry for Mycolactone Virulence. Organic Letters, 2019, 21, 5853-5857.	4.6	11
102	Laboratory Diagnosis of Buruli Ulcer: Challenges and Future Perspectives. , 2019, , 183-202.		11
103	Bacterial genome-wide association study of hyper-virulent pneumococcal serotype 1 identifies genetic variation associated with neurotropism. Communications Biology, 2020, 3, 559.	4.4	11
104	wIRA: hyperthermia as a treatment option for intracellular bacteria, with special focus on Chlamydiae and Mycobacteria. International Journal of Hyperthermia, 2020, 37, 373-383.	2.5	11
105	Nanotechnological immunoassay for rapid label-free analysis of candidate malaria vaccines. Nanoscale, 2021, 13, 2338-2349.	5.6	11
106	Exudate collection using wound spongesâ€”An easy, nonâ€invasive and reliable method to explore protease activities in ulcers. Wound Repair and Regeneration, 2017, 25, 320-326.	3.0	10
107	Thermal field formation during wIRA-hyperthermia: temperature measurements in skin and subcutis of piglets as a basis for thermotherapy of superficial tumors and local skin infections caused by thermosensitive microbial pathogens. International Journal of Hyperthermia, 2019, 36, 937-951.	2.5	10
108	Limited Genetic Diversity of Hepatitis B Virus in the General Population of the Offin River Valley in Ghana. PLoS ONE, 2016, 11, e0156864.	2.5	10

#	Article	IF	Citations
109	A Case of Cutaneous Tuberculosis in a Buruli Ulcerâ€“Endemic Area. PLoS Neglected Tropical Diseases, 2012, 6, e1751.	3.0	9
110	Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2020, 14, e0008357.	3.0	9
111	Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine. Malaria Journal, 2009, 8, 314.	2.3	8
112	Lack of antigenic diversification of major outer membrane proteins during clonal waves ofNeisseria meningitidisserogroup A colonization and disease. Pathogens and Disease, 2013, 67, 4-10.	2.0	7
113	Spatiotemporal Co-existence of Two Mycobacterium ulcerans Clonal Complexes in the Offin River Valley of Ghana. PLoS Neglected Tropical Diseases, 2016, 10, e0004856.	3.0	7
114	Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunization. BMC Biotechnology, 2016, 16, 83.	3.3	7
115	Buruli Ulcer in Africa. , 2019, , 43-60.		6
116	Inhibition of the SEC61 translocon by mycolactone induces a protective autophagic response controlled by EIF2S1-dependent translation that does not require ULK1 activity. Autophagy, 2021, , 1-19.	9.1	6
117	Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009. F1000Research, 2014, 3, 264.	1.6	6
118	Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	4.1	6
119	Development of a Temperature-Switch PCR-Based SNP Typing Method for Mycobacterium ulcerans. PLoS Neglected Tropical Diseases, 2012, 6, e1904.	3.0	5
120	Transmission of Hepatitis B and D Viruses in an African Rural Community. MSystems, 2018, 3, .	3.8	5
121	Spontaneous point mutations in the capsule synthesis locus leading to structural and functional changes of the capsule in serogroup A meningococcal populations. Virulence, 2018, 9, 1138-1149.	4.4	5
122	Introduction of Mycobacterium ulcerans disease in the Bankim Health District of Cameroon follows damming of the MapÃ© River. PLoS Neglected Tropical Diseases, 2020, 14, e0008501.	3.0	5
123	Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1Î², are linked to fibrin formation in Buruli ulcer lesions. PLoS Pathogens, 2022, 18, e1010280.	4.7	5
124	Development of a virosomal malaria vaccine candidate: from synthetic peptide design to clinical concept validation. Future Virology, 2012, 7, 779-790.	1.8	4
125	Complete Healing of a Laboratory-Confirmed Buruli Ulcer Lesion after Receiving Only Herbal Household Remedies. PLoS Neglected Tropical Diseases, 2015, 9, e0004102.	3.0	4
126	An Antigen Capture Assay for the Detection of Mycolactone, the Polyketide Toxin of Mycobacterium ulcerans. Journal of Immunology, 2021, 206, 2753-2762.	0.8	3

#	Article	IF	Citations
127	Title is missing!. Angewandte Chemie, 2003, 115, 2470-2473.	2.0	2
128	Virosomal technology in malaria vaccine development. Future Virology, 2010, 5, 247-250.	1.8	2
129	Loss of Genomic Diversity in a Neisseria meningitidis Clone Through a Colonization Bottleneck. Genome Biology and Evolution, 2018, 10, 2102-2109.	2.5	2
130	Overview: Development of Drugs Against Mycobacterium ulcerans. Methods in Molecular Biology, 2022, 2387, 185-187.	0.9	2
131	Exploiting Conformationally Constrained Peptidomimetics and an Efficient Human-Compatible Delivery System in Synthetic Vaccine Design. ChemBioChem, 2002, 3, 270-270.	2.6	1
132	Investigation of Mycobacterium ulcerans Glycan Interactions Using Glycan and Surface Plasmon. Methods in Molecular Biology, 2022, 2387, 29-40.	0.9	1
133	Overview: Mycolactone, the Macrolide Toxin of Mycobacterium ulcerans. Methods in Molecular Biology, 2022, 2387, 105-108.	0.9	1
134	Cyclic Peptidomimetics Derived from the Apical Membrane Antigen I ofPlasmodium falciparum and Their Use in Malaria Vaccine Design. Helvetica Chimica Acta, 2003, 86, 3638-3647.	1.6	0
135	The cell surface protein MUL_3720 confers binding of the skin pathogen Mycobacterium ulcerans to sulfated glycans and keratin. PLoS Neglected Tropical Diseases, 2021, 15, e0009136.	3.0	0
136	Overview: Mycobacterium ulcerans Disease (Buruli Ulcer). Methods in Molecular Biology, 2022, 2387, 3-6.	0.9	0
137	Efficacy of an acid-oxidising solution (AOS) against Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 2021, , AAC0087021.	3.2	0
138	Chronic wounds in Sierra Leone: Searching for Buruli ulcer, a NTD caused by Mycobacterium ulcerans, at Masanga Hospital. PLoS Neglected Tropical Diseases, 2021, 15, e0009862.	3.0	0